HK1175711A1 - Formulation for hgh and rhigf-1 combination hgh rhigf-1 - Google Patents

Formulation for hgh and rhigf-1 combination hgh rhigf-1

Info

Publication number
HK1175711A1
HK1175711A1 HK13103070.2A HK13103070A HK1175711A1 HK 1175711 A1 HK1175711 A1 HK 1175711A1 HK 13103070 A HK13103070 A HK 13103070A HK 1175711 A1 HK1175711 A1 HK 1175711A1
Authority
HK
Hong Kong
Prior art keywords
rhigf
hgh
formulation
combination
hgh rhigf
Prior art date
Application number
HK13103070.2A
Other languages
English (en)
Chinese (zh)
Inventor
Enona Gopinath
Susan Park
Tsutomu Arakawa
Jol Richard
Fabio Fais
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of HK1175711A1 publication Critical patent/HK1175711A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK13103070.2A 2009-11-17 2013-03-12 Formulation for hgh and rhigf-1 combination hgh rhigf-1 HK1175711A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26185909P 2009-11-17 2009-11-17
PCT/EP2010/006996 WO2011060922A1 (en) 2009-11-17 2010-11-17 Formulation for hgh and rhigf-1 combination

Publications (1)

Publication Number Publication Date
HK1175711A1 true HK1175711A1 (en) 2013-07-12

Family

ID=43661042

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13103070.2A HK1175711A1 (en) 2009-11-17 2013-03-12 Formulation for hgh and rhigf-1 combination hgh rhigf-1

Country Status (15)

Country Link
US (2) US20120270782A1 (xx)
EP (1) EP2501367B1 (xx)
JP (2) JP6084036B2 (xx)
KR (1) KR101614983B1 (xx)
CN (1) CN102665691B (xx)
AU (1) AU2010321225B2 (xx)
BR (1) BR112012011539A8 (xx)
CA (1) CA2780554C (xx)
ES (1) ES2532007T3 (xx)
HK (1) HK1175711A1 (xx)
IN (1) IN2012DN02861A (xx)
MX (1) MX2012005195A (xx)
RU (1) RU2558821C2 (xx)
UA (1) UA108994C2 (xx)
WO (1) WO2011060922A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130769A2 (en) 2005-06-02 2006-12-07 Tercica, Inc. Methods for treatment of growth disorders
US20140194356A1 (en) 2011-07-25 2014-07-10 Sandoz Ag Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
KR102534017B1 (ko) * 2014-10-23 2023-05-19 암젠 인크 약제학적 제형의 점도 감소
US20190064147A1 (en) * 2015-01-18 2019-02-28 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
EP3257524B1 (en) 2015-02-11 2020-08-26 Gmax Biopharm LLC Stabilized solution preparation of pharmaceutical glp-1r antibody fusion protein
JP2019511531A (ja) * 2016-04-13 2019-04-25 メディミューン，エルエルシー 高濃度のタンパク質ベース治療薬を含有する医薬組成物における安定化化合物としてのアミノ酸の使用
US20210087236A1 (en) * 2016-08-15 2021-03-25 The University Of North Carolina At Chapel Hill Tardigrade disordered proteins as protein stabilizers
MA46466A (fr) 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
US10953074B2 (en) * 2017-01-08 2021-03-23 Richard D. Lippman Composition and method for improving sensorineural hearing
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
AU2021364523A1 (en) * 2020-10-19 2023-04-06 Oak Hill Bio Limited Compositions suitable for use in neonates
CA3238895A1 (en) * 2021-11-26 2023-06-01 Genexine, Inc. High-concentration administration formulation of hgh fusion protein

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DK0652766T4 (da) * 1992-07-31 2008-06-09 Genentech Inc Vandigt præparat indeholdende humant væksthormon
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
KR19980701351A (ko) * 1995-01-13 1998-05-15 슈타르 피아 성장호르몬 및 Ｘ-Ｌｙｓ를 함유하는 안정화된 약제조제물(A STABILIZED PHARMACEUTICAL FORMULATION COMPRISING A GROWTH HORMONE AND X-Lys
JP2001522813A (ja) * 1997-11-07 2001-11-20 カイロン コーポレイション 新規のｉｇｆ−ｉ組成物およびその使用
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
BR0013162A (pt) * 1999-07-12 2002-05-28 Grandis Biotech Gmbh Formulações de hormÈnio de crescimento
HU227347B1 (en) * 1999-10-04 2011-04-28 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
WO2003072060A2 (en) * 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
CN1665540A (zh) * 2002-07-09 2005-09-07 桑多斯股份公司 含1,2－丙二醇的高浓度人生长激素液体制剂
WO2006130769A2 (en) 2005-06-02 2006-12-07 Tercica, Inc. Methods for treatment of growth disorders
US20070135343A1 (en) * 2005-11-01 2007-06-14 Wyeth Sodium chloride solution for drug reconstitution or dilution
HUE031329T2 (hu) * 2006-07-06 2017-07-28 Daewoong Co Ltd Humán növekedési hormon stabil folyékony készítménye
JP5168604B2 (ja) * 2008-05-08 2013-03-21 味の素株式会社 タンパク質のリフォールディング方法

Also Published As

Publication number Publication date
US20120270782A1 (en) 2012-10-25
AU2010321225A1 (en) 2012-06-07
AU2010321225B2 (en) 2015-12-03
BR112012011539A2 (pt) 2016-06-28
EP2501367B1 (en) 2015-01-21
KR101614983B1 (ko) 2016-04-22
BR112012011539A8 (pt) 2017-12-26
JP2016020395A (ja) 2016-02-04
RU2012124985A (ru) 2013-12-27
CN102665691B (zh) 2015-05-27
JP6084036B2 (ja) 2017-02-22
CA2780554A1 (en) 2011-05-26
RU2558821C2 (ru) 2015-08-10
UA108994C2 (uk) 2015-07-10
CN102665691A (zh) 2012-09-12
KR20120104251A (ko) 2012-09-20
IN2012DN02861A (xx) 2015-07-24
JP6143827B2 (ja) 2017-06-07
EP2501367A1 (en) 2012-09-26
JP2013510893A (ja) 2013-03-28
ES2532007T3 (es) 2015-03-23
WO2011060922A1 (en) 2011-05-26
US20170143834A1 (en) 2017-05-25
CA2780554C (en) 2017-08-15
MX2012005195A (es) 2012-06-12

Similar Documents

Publication Publication Date Title
HK1175711A1 (en) Formulation for hgh and rhigf-1 combination hgh rhigf-1
GB2469580B (en) Delivery method and compositions
EP2515946A4 (en) NANOCONJUGATES AND COMPOSITIONS OF NANOCONJUGATES
EP2404713A4 (en) JOINT UNIT FOR ROBOT AND ROBOT
ZA201106050B (en) Dye-polymers formulations
ZA201200719B (en) Pharmaceutical formulation
ZA201106755B (en) Fast-acting insulin formulation
EP2405826A4 (en) ACTIVE OS SCREW
GB0907003D0 (en) Formulation
GB0919210D0 (en) Formulations
GB2462761B (en) Protein formulation
EP2465512A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING PAIN
GB0822633D0 (en) Formulation
IL219300A (en) Equipment for positioning and stabilizing the skin
WO2010114629A9 (en) Formulation
HK1219047A1 (zh) 調節的肺部給藥製劑
HK1201759A1 (en) 4-methylpyrazole formulations 4-
GB0800788D0 (en) Niovel formulation
EP2440159A4 (en) JOINT IMPLANT
IL213413A0 (en) Palonosetron formulation
GB0814376D0 (en) Formulation
GB0917792D0 (en) Delivery agent
GB0911213D0 (en) Formulation
IL217390A0 (en) Formulations
GB0902472D0 (en) Formulation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201120